Weight-Loss Drug Tirzepatide More Effective in Women, Study Finds

New analysis reveals women lose significantly more weight than men on tirzepatide, but experience higher rates of nausea.

Researchers analyzed data from four clinical trials involving 4,677 obese adults, including 2,999 women and 1,678 men.
Women lost up to 24.6% of their body weight on tirzepatide, compared to 18.1% for men.
The trials, funded by Eli Lilly, tested tirzepatide against a placebo over a period of 72 to 88 weeks.
While the safety profile was similar for both sexes, women reported higher rates of nausea and vomiting.
Further research is needed to understand why women experience greater weight reduction on tirzepatide.